Portfoliotracker

Olema Oncology, Inc.

OLMA · NASDAQGS · Healthcare Biotechnology 9/100 E

7,360 $
▼ −0,200 (−2,65 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:19
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score9 / 100 Market cap744 mil. $ P/E– Forward P/E-2,6 P/S– P/B2,0 EV/EBITDA– Dividend yield– FCF yield-22,17 % EPS-2,40 $ Net margin0,0 % Return on equity-69,8 % Beta2,02 Debt / equity0,01
52-week range 6,24 to 36,26
3-month average volume1,3 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as Olema Pharmaceuticals, Inc. and changed its name to Olema Oncology, Inc. in November 2026. Olema Oncology, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Website
olema.com
Employees
131
Country
United States
Fiscal year end
31. 12.
Data since
19. 11. 2020

Explore further

Similar companies ORICCGEMPRAXFDMTALXO

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account